RARE DISEASE
Classic glucose transporter type 1 deficiency syndrome
Classic glucose transporter type 1 deficiency syndrome
Classic glucose transporter type 1 deficiency syndrome
Synonyms: Classic GLUT1 deficiency syndrome, Classic GLUT1-DS, De Vivo disease, Encephalopathy due to GLUT1 deficiency
Synonyms: Classic GLUT1 deficiency syndrome, Classic GLUT1-DS, De Vivo disease, Encephalopathy due to GLUT1 deficiency
Synonyms: Classic GLUT1 deficiency syndrome, Classic GLUT1-DS, De Vivo disease, Encephalopathy due to GLUT1 deficiency
Drug discovery
3
drugs
With orphan designations
Overview
Classic Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS) - rare autosomal dominant neurometabolic disorder caused by SLC2A1 mutations, impairing glucose transport across the blood-brain barrier. Core features include infantile-onset epilepsy (e.g., absence, myoclonic-atonic seizures), acquired microcephaly, developmental delay, and paroxysmal movement disorders (ataxia, dystonia). Diagnosis relies on hypoglycorrhachia (CSF/blood glucose ratio <0.4) and genetic confirmation. Early ketogenic diet therapy improves seizures and motor symptoms but does not reverse cognitive deficits [1][2][6].
Burden
Neurological: Persistent intellectual disability, speech deficits, and movement disorders despite treatment [9][16].
Lifelong management: Ketogenic diet adherence challenges (18% non-compliance), with risks of atherosclerosis and bone demineralization [5][9].
Psychosocial impact: Developmental delays, therapy needs (physical, occupational), and caregiver strain [19][20].
Therapies
First-line: Ketogenic diet (≥90% fat calories) to bypass glucose dependency, improving seizures (83% efficacy) and movement disorders [5][9][16].
Avoidances: Phenobarbital, valproic acid (worsen symptoms) [6][8].
Emerging options: Gene therapy, triheptanoin, and ketone esters under investigation [5][17].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases
Research Papers
144 drug discovery papers about Classic glucose transporter type 1 deficiency syndrome, with 1 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
144 drug discovery papers about Classic glucose transporter type 1 deficiency syndrome, with 1 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-03-15 | "Not always the magic bullet"-Insufficient seizure control by ketogenic dietary therapies in Glut1 Deficiency Syndrome.
Ketogenic dietary therapies (KDTs) are the treatment of choice for Glut1 Deficiency Syndrome (Glut1DS), providing dietary ketones as an alternative fuel to the brain and effectively controlling seizures. Recent evidence indicates insufficient seizure control in Glut1DS patients despite adequate KDT and ketosis. Fifty-three patients, diagnosed with Glut1DS and treated by KDT, were followed in a single-center outpatient clinic from 2000 to 2023. Epilepsy, present in 44 patients, was analyzed for seizure control, EEG changes, and potential correlations to clinical and genetic features. Epilepsy response to KDT was defined as a >90% seizure reduction on KDT monotherapy. On KDT monotherapy 27/44 (61%) patients became >90% seizure free, rated as responders. 17/44 were non-responders. Within this group, 10/17 patients responded to KDT plus antiseizure comedication. In 7 patients, KDT plus antiseizure comedication failed to control seizures. No correlations of seizure control to gender, age at start or type of KDT, or SLC2A1 variants were observed. In responders (n = 27), EEG epileptic activity, evident in 15/27 patients, improved on KDT in 5 patients. In non-responders (n = 17), EEG epileptic activity was evident in 14/17 and improved on KDT in 9 patients. EEG background slowing prior to KDT normalized in KDT in all responders (4/27), but in none of the non-responders (4/17). Epilepsy is a dominant feature of Glut1DS. KDT provides efficient seizure control, but failure to control epilepsy is more common than expected. KDT epilepsy response did not correlate with seizure type, clinical, or genetic features, emphasizing the complexity of this entity. Add-on antiseizure medication can be effective in some patients, without individual drug superiority. Epileptic activity on EEG did not prove a good marker for outcome, but reversible EEG background slowing on KDT might be predictive for favorable seizure control. Impaired glucose transport into the brain causes a brain energy crisis termed Glut1 Deficiency. Ketogenic diets mimic fasting, provide ketones as an alternative fuel, and effectively restore brain function. In our study, this worked for ca. 60% of patients. To our surprise, epilepsy persisted in about 40% of patients despite ketogenic diets for reasons unknown. Additional medication against epilepsy randomly helped in some patients. We analyzed many parameters without finding obvious explanations. Electrical brain activity improvement on ketogenic diets might be a future marker for efficient seizure control.
2026-02-05 | In search of "what really matters": Insights from a web-based survey on Patient-Centered Outcomes in GLUT1DS.
Glucose Transporter Type 1 Deficiency Syndrome (GLUT1DS) is a rare genetic disorder caused by mutations in the SLC2A1 gene. Core symptoms include epilepsy, movement disorders, and neurocognitive impairment. While ketogenic dietary therapies remain the gold standard for treatment, challenges persist in ensuring adherence, with varying responses across patients. Limited knowledge exists regarding the broader impact of GLUT1DS on patients and caregivers, highlighting the need for a patient-centered care approach. In collaboration with the Italian GLUT1DS Association, a survey was developed to assess Patient-Centered Outcomes, covering demographic data, symptoms, daily life challenges and treatment experiences. The survey was distributed online to patients and caregivers, yielding 83 responses. Data were analyzed using descriptive statistics, t-tests, and chi-square analyses to explore the relationship between core symptoms and broader life impacts. Movement disorders were identified as a major barrier to daily activities, particularly leisure and social engagement. Cognitive impairments were linked to academic struggles, and speech/language impairments, especially dysarthria, emerged as a significant burden. Sleep disturbances were common, with restless sleep in younger patients and excessive daytime sleepiness in older ones. Although ketogenic therapies improved energy and memory, challenges in patient autonomy persisted. Delayed disease awareness and difficulty with educational and occupational transitions were also reported. GLUT1DS has a broad impact beyond core symptoms. A comprehensive, multidisciplinary care approach is essential for optimizing quality of life. These findings offer critical insights for refining clinical management strategies and shaping future research on patient-reported outcomes in GLUT1DS.
2025-09-30 | Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome.
The ketogenic diet (KD) is the standard treatment for glucose transporter type 1 deficiency syndrome (GLUT1-DS), typically yielding seizure reduction and cognitive/motor gains. However, a small subset of patients shows limited or no clinical benefit. This phenomenon, referred to as "KD resistance," remains poorly understood and inconsistently defined. We propose a working definition, outline evaluation domains, summarize candidate mechanisms, and indicate management steps. Narrative review of published evidence and expert opinion across clinical, biochemical, EEG, and adherence domains. KD resistance may be considered when all are present: (1) confirmed therapeutic ketosis (serial blood β-hydroxybutyrate ≥2.0-2.5 mmol/L on repeated measurements); (2) adequate dietary adherence verified by dietetic assessment and, when available, validated tools; (3) sufficient trial duration (≥3 months; longer for primarily cognitive/motor goals); and (4) lack of meaningful improvement on symptom-relevant standardized measures. EEG interictal epileptiform discharge burden can be used as an adjunct marker but is not required. KD resistance may involve several dimensions: failure to achieve therapeutic ketosis, lack of symptom improvement despite confirmed ketosis, or challenges with adherence that limit efficacy. Possible contributing factors include genotypic variability in SLC2A1, mitochondrial dysfunction, impaired blood-brain barrier transport, hormonal influences, and epigenetic regulation. We outline a multidomain evaluation framework with suggested metrics, summarize candidate mechanisms (ketone transport/utilization, mitochondrial function, neurotransmission, ion channels/neuromodulators, inflammation/oxidative stress, epigenetic regulation), and indicate when to introduce a KD-compatible anti-seizure medication. The proposed definition and framework standardize terminology and reporting, guide decisions for suboptimal responders, and set priorities for multicenter validation.
2025-09-04 | Adult-onset non-kinesigenic paroxysmal dyskinesia in GLUT1 deficiency syndrome.
Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a disorder caused by variants in the SLC2A1 gene. Clinical features are heterogeneous, from the classic presentation to milder later-onset phenotypes. We describe the case of a male patient with adult-onset paroxysmal dyskinesia in a mild phenotype of GLUT1DS (NM_006516.4 c.998G > A, p. Arg333Gln).
2025-06-19 | Structural Insights into the Substrate Egress Pathways Explains Specificity and Inhibition of Human Glucose Transporters (GLUT1 and GLUT9).
Glucose transporters (GLUTs) play critical roles in cellular energy homeostasis and substrate-specific transport. Dysfunctional mutations can cause GLUT1 deficiency syndrome, and excessive expression of GLUT1 is linked to cancer progression, while abnormal regulation of urate transport by GLUT9 is associated with hyperuricemia and gout. In this study, machine-learning-driven molecular dynamics simulations have been employed to investigate the mechanistic insights into the substrate egress pathways of GLUT1 and GLUT9, including the inhibition mechanism of GLUT9 by apigenin. Our findings reveal that intracellular helices play a crucial role in facilitating the transition from inward-closed to -open conformations in both transporters. Additionally, aromatic residues, F291 and W388 in GLUT1 and W336 and F435 in GLUT9, are identified as key mediators of conformational changes. Analysis of substrate exit pathways provides mechanistic insights into transport profiles and aligns with clinically observed mutations. Furthermore, the inhibitory effect of apigenin on GLUT9 is shown to arise from steric hindrance due to increased substrate size rather than stable interactions. These findings enhance our understanding of GLUT transporter dynamics and highlight the potential of targeting substrate pathways for therapeutic intervention.
2026-03-15 | "Not always the magic bullet"-Insufficient seizure control by ketogenic dietary therapies in Glut1 Deficiency Syndrome.
Ketogenic dietary therapies (KDTs) are the treatment of choice for Glut1 Deficiency Syndrome (Glut1DS), providing dietary ketones as an alternative fuel to the brain and effectively controlling seizures. Recent evidence indicates insufficient seizure control in Glut1DS patients despite adequate KDT and ketosis. Fifty-three patients, diagnosed with Glut1DS and treated by KDT, were followed in a single-center outpatient clinic from 2000 to 2023. Epilepsy, present in 44 patients, was analyzed for seizure control, EEG changes, and potential correlations to clinical and genetic features. Epilepsy response to KDT was defined as a >90% seizure reduction on KDT monotherapy. On KDT monotherapy 27/44 (61%) patients became >90% seizure free, rated as responders. 17/44 were non-responders. Within this group, 10/17 patients responded to KDT plus antiseizure comedication. In 7 patients, KDT plus antiseizure comedication failed to control seizures. No correlations of seizure control to gender, age at start or type of KDT, or SLC2A1 variants were observed. In responders (n = 27), EEG epileptic activity, evident in 15/27 patients, improved on KDT in 5 patients. In non-responders (n = 17), EEG epileptic activity was evident in 14/17 and improved on KDT in 9 patients. EEG background slowing prior to KDT normalized in KDT in all responders (4/27), but in none of the non-responders (4/17). Epilepsy is a dominant feature of Glut1DS. KDT provides efficient seizure control, but failure to control epilepsy is more common than expected. KDT epilepsy response did not correlate with seizure type, clinical, or genetic features, emphasizing the complexity of this entity. Add-on antiseizure medication can be effective in some patients, without individual drug superiority. Epileptic activity on EEG did not prove a good marker for outcome, but reversible EEG background slowing on KDT might be predictive for favorable seizure control. Impaired glucose transport into the brain causes a brain energy crisis termed Glut1 Deficiency. Ketogenic diets mimic fasting, provide ketones as an alternative fuel, and effectively restore brain function. In our study, this worked for ca. 60% of patients. To our surprise, epilepsy persisted in about 40% of patients despite ketogenic diets for reasons unknown. Additional medication against epilepsy randomly helped in some patients. We analyzed many parameters without finding obvious explanations. Electrical brain activity improvement on ketogenic diets might be a future marker for efficient seizure control.
2026-02-05 | In search of "what really matters": Insights from a web-based survey on Patient-Centered Outcomes in GLUT1DS.
Glucose Transporter Type 1 Deficiency Syndrome (GLUT1DS) is a rare genetic disorder caused by mutations in the SLC2A1 gene. Core symptoms include epilepsy, movement disorders, and neurocognitive impairment. While ketogenic dietary therapies remain the gold standard for treatment, challenges persist in ensuring adherence, with varying responses across patients. Limited knowledge exists regarding the broader impact of GLUT1DS on patients and caregivers, highlighting the need for a patient-centered care approach. In collaboration with the Italian GLUT1DS Association, a survey was developed to assess Patient-Centered Outcomes, covering demographic data, symptoms, daily life challenges and treatment experiences. The survey was distributed online to patients and caregivers, yielding 83 responses. Data were analyzed using descriptive statistics, t-tests, and chi-square analyses to explore the relationship between core symptoms and broader life impacts. Movement disorders were identified as a major barrier to daily activities, particularly leisure and social engagement. Cognitive impairments were linked to academic struggles, and speech/language impairments, especially dysarthria, emerged as a significant burden. Sleep disturbances were common, with restless sleep in younger patients and excessive daytime sleepiness in older ones. Although ketogenic therapies improved energy and memory, challenges in patient autonomy persisted. Delayed disease awareness and difficulty with educational and occupational transitions were also reported. GLUT1DS has a broad impact beyond core symptoms. A comprehensive, multidisciplinary care approach is essential for optimizing quality of life. These findings offer critical insights for refining clinical management strategies and shaping future research on patient-reported outcomes in GLUT1DS.
2025-09-30 | Toward a working definition of ketogenic diet resistance in GLUT1 deficiency syndrome.
The ketogenic diet (KD) is the standard treatment for glucose transporter type 1 deficiency syndrome (GLUT1-DS), typically yielding seizure reduction and cognitive/motor gains. However, a small subset of patients shows limited or no clinical benefit. This phenomenon, referred to as "KD resistance," remains poorly understood and inconsistently defined. We propose a working definition, outline evaluation domains, summarize candidate mechanisms, and indicate management steps. Narrative review of published evidence and expert opinion across clinical, biochemical, EEG, and adherence domains. KD resistance may be considered when all are present: (1) confirmed therapeutic ketosis (serial blood β-hydroxybutyrate ≥2.0-2.5 mmol/L on repeated measurements); (2) adequate dietary adherence verified by dietetic assessment and, when available, validated tools; (3) sufficient trial duration (≥3 months; longer for primarily cognitive/motor goals); and (4) lack of meaningful improvement on symptom-relevant standardized measures. EEG interictal epileptiform discharge burden can be used as an adjunct marker but is not required. KD resistance may involve several dimensions: failure to achieve therapeutic ketosis, lack of symptom improvement despite confirmed ketosis, or challenges with adherence that limit efficacy. Possible contributing factors include genotypic variability in SLC2A1, mitochondrial dysfunction, impaired blood-brain barrier transport, hormonal influences, and epigenetic regulation. We outline a multidomain evaluation framework with suggested metrics, summarize candidate mechanisms (ketone transport/utilization, mitochondrial function, neurotransmission, ion channels/neuromodulators, inflammation/oxidative stress, epigenetic regulation), and indicate when to introduce a KD-compatible anti-seizure medication. The proposed definition and framework standardize terminology and reporting, guide decisions for suboptimal responders, and set priorities for multicenter validation.
2025-09-04 | Adult-onset non-kinesigenic paroxysmal dyskinesia in GLUT1 deficiency syndrome.
Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a disorder caused by variants in the SLC2A1 gene. Clinical features are heterogeneous, from the classic presentation to milder later-onset phenotypes. We describe the case of a male patient with adult-onset paroxysmal dyskinesia in a mild phenotype of GLUT1DS (NM_006516.4 c.998G > A, p. Arg333Gln).
2025-06-19 | Structural Insights into the Substrate Egress Pathways Explains Specificity and Inhibition of Human Glucose Transporters (GLUT1 and GLUT9).
Glucose transporters (GLUTs) play critical roles in cellular energy homeostasis and substrate-specific transport. Dysfunctional mutations can cause GLUT1 deficiency syndrome, and excessive expression of GLUT1 is linked to cancer progression, while abnormal regulation of urate transport by GLUT9 is associated with hyperuricemia and gout. In this study, machine-learning-driven molecular dynamics simulations have been employed to investigate the mechanistic insights into the substrate egress pathways of GLUT1 and GLUT9, including the inhibition mechanism of GLUT9 by apigenin. Our findings reveal that intracellular helices play a crucial role in facilitating the transition from inward-closed to -open conformations in both transporters. Additionally, aromatic residues, F291 and W388 in GLUT1 and W336 and F435 in GLUT9, are identified as key mediators of conformational changes. Analysis of substrate exit pathways provides mechanistic insights into transport profiles and aligns with clinically observed mutations. Furthermore, the inhibitory effect of apigenin on GLUT9 is shown to arise from steric hindrance due to increased substrate size rather than stable interactions. These findings enhance our understanding of GLUT transporter dynamics and highlight the potential of targeting substrate pathways for therapeutic intervention.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Classic glucose transporter type 1 deficiency syndrome.
3 orphan drug designations for Classic glucose transporter type 1 deficiency syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
mixture of decanoic acid (C10; tricaprin) and octanoic acid (C8; tricaprylin) | small molecules | FDA | 2024-07-16 | — | Aimmune Nestlé US R&D LLC |
Triheptanoin | small molecules | EMA | 2015-05-21 | — | Ultragenyx Netherlands B.V. |
triheptanoin | small molecules | FDA | 2014-10-21 | — | Ultragenyx Pharmaceutical, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.